−$13.77 (32.85%) At close $28.15 · Tue
☾After Hours +$0.11 (0.40%) Nov 3, 7:59 PM ET
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
The Motley Fool
Why Indivior Pharmaceuticals Stock Topped the Market TodayIndivior Pharmaceuticals completed its merger with Supernus Pharmaceuticals on November 2, 2026, creating a leading CNS biopharmaceutical company. The combined entity will operate under the Supernus name and ticker, with Indivior shareholders receiving a $1 billion special cash dividend and owning approximately 56.5% of the merged company. The merger aims to achieve $125 million in annual cost synergies.
Zacks Investment Research
Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue EstimatesSupernus Pharmaceuticals beat Q3 2026 earnings expectations with $0.93 EPS versus consensus of $0.49, representing an 89.80% surprise. Revenue of $226.77 million also exceeded estimates by 1.39%. However, the stock has underperformed the market by 17.3% year-to-date and carries a Zacks Rank #5 (Strong Sell) rating due to unfavorable estimate revision trends ahead of the earnings release.
GlobeNewswire Inc.
Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl)Supernus Pharmaceuticals announced that the FDA has granted seven years of orphan-drug market exclusivity for ONAPGO (apomorphine HCl), a subcutaneous infusion device for treating motor fluctuations in advanced Parkinson's disease patients. The exclusivity period began February 3, 2025. Additionally, the company submitted a supplemental New Drug Application for a second supplier with expected FDA approval by mid-2027.
Zacks Investment Research
BIIB's Q3 Earnings Beat, New Drugs Aid Sales, '26 EPS View TightenedBiogen beat Q3 2026 earnings and revenue estimates with adjusted EPS of $2.62 and revenues of $2.80 billion. Growth drugs Skyclarys, Qalsody, Zurzuvae, and acquired Apellis products drove strong performance, with growth portfolio revenues rising ~50% year-over-year.
However, legacy MS portfolio declined 13% and biosimilar sales fell 19%. The company tightened 2026 EPS guidance to $15.95-$16.75 while maintaining mid-single-digit revenue growth expectations.
Headlines open the publisher's site.
